JPRN-jRCT2080222895未知3 期
M518101 phase III 52-Week long term study in plaque psoriasis and palmoplantar keratoderma patients
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients diagnosed with plaque psoriasis or palmoplantar keratoderma
排除标准
- 未提供
研究者
相似试验
未知
3 期
MK-0431/ONO-5435 Phase III Clinical Study - Long-term Treatment Study for Patients with Type 2 Diabetes MellitusType 2 Diabetes MellitusJPRN-jRCT2080220289ONO PHARMACEUTICAL CO.,LTD.
进行中（未招募）
不适用
A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT) and to evaluate the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine in the fourth year of life. - 10PN-PD-DIT-046 EXT:002 Y2A booster vaccination study against Streptococcus pneumoniae in subjects aged 36-46 months and a two-dose vaccination against Streptococcus pneumoniae of age-matched unprimed children.EUCTR2008-003950-14-SEGlaxoSmithKline Biologicals210
进行中（未招募）
1 期
A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT) and to evaluate the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine in the fourth year of life. - 10PN-PD-DIT-046 EXT:002 Y2A booster vaccination study against Streptococcus pneumoniae in subjects aged 36-46 months and a two-dose vaccination against Streptococcus pneumoniae of age-matched unprimed children.EUCTR2008-003950-14-SKGlaxoSmithKline Biologicals210
进行中（未招募）
不适用
A phase III long-term follow-up study to assess antibody persistence and immunological memory in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccination study 10PN-PD-DIT-001 and booster vaccination study 10PN-PD-DIT-007 and assessment of immune responses following a 2-dose catch-up immunization with GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal vaccine in the 6th year of life. - 10PN-PD-DIT-041 EXT:007 Y1, Y2, Y4Subjects who participated in booster study 10PN-PD-DiT-007 in Poland and who received the full vaccination course (i.e. four doses) with a pneumococcal vaccine, co-administered with DTPa-HBV-IPV/Hib, will be followed-up to evaluate the long-term persistence of antibodies at approximately 30, 42 and 66 months of age and will be vaccinated in the 6th year of life against Streptococcus pneumoniae in parallel with age-matched unprimed subjects.MedDRA version: 12.1Level: LLTClassification code 10061353Term: Pneumococcal infectionMedDRA version: 12.1Level: LLTClassification code 10061190Term: Haemophilus infectionEUCTR2007-005392-34-PLGlaxoSmithKline Biologicals
进行中（未招募）
不适用
A phase III long-term follow-up study to assess immunological memory induced following primary and booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT), through evaluation of early antibody responses after an additional dose of 10Pn-PD-DiT at 40-48 months of age, to evaluate in the fourth year of life, the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine and the impact of pneumococcal vaccination on nasopharyngeal carriage. - 10PN-PD-DIT-042 EXT 014Subjects aged 31-44 months previously vaccinated with GSK Biologicals’ 10Pn-PD-DiT vaccine and age-matched unprimed children who participated in study 10PN-PD-DIT-014 (107137).EUCTR2008-008104-41-CZGlaxoSmithKline Biologicals690